John Quale Travel Fellowships

The John Quale Travel Fellowship Program is a special opportunity for early career investigators interested in bladder cancer research to attend the annual Bladder Cancer Think Tank Meeting.

The $1,700 travel fellowships awarded each year are intended to defray travel-related costs for attending the meeting. Hosted by the Bladder Cancer Advocacy Network (BCAN), the primary mission of this meeting is to enhance collaboration among physicians and researchers who are dedicated to the prevention, diagnosis, and treatment of bladder cancer. This is a unique opportunity to meet and learn from leaders in the field. The Travel Fellowship Program seeks to engage more early-career individuals with interests related to bladder cancer including basic scientists, urologists, oncologists, and pathologists.  Please contact BCAN at if you have questions. The 2017 John Quale Travel Fellowship application instructions, are available here: JQTF Guidelines 2017.

2016 John Quale Travel Fellows

  • Samuel Funt, MD, Memorial Sloan-Kettering Cancer Center
  • Matthew Mossansen, MD, Urologic Oncology Fellow, Massachusetts General Hospital
  • Tracy Rose, MD, University of North Carolina at Chapel Hill
  • Debasish Sundi, MD, University of Texas M.D. Anderson Cancer Center

2015 John Quale Travel Fellows

  • Abdul R. Banday, Ph.D., M.S. Postdoctoral Fellow, Laboratory of Translational Genomics National Cancer Institute, NIH NCI Division of Cancer Epidemiology and Genetics
  • Max Kates, M.D. Resident, Department of Urology Johns Hopkins Medical Institutions
  • Huyen T. Nguyen, Ph.D. Postdoctoral Researcher, Department of Radiology The Ohio State University
  • Randy Sweis, M.D. Fellow, Division of Hematology/Oncology The University of Chicago

2014 John Quale Travel Fellows

  • Philip Ho, MD, Urologic Oncology Fellow, University of Texas M.D. Anderson Cancer Center
  • Tim Lautenschlaeger, MD , Research Assistant Professor, Senior Radiation Oncology Resident, The Ohio State University
  • Young Lee, PhD, Postdoctoral Fellow, National Cancer Institute, Urologic Oncology Branch
  • Anirban Mitra, MD, PhD, Senior Research Associate, Department of Pathology and Laboratory Medicine / Center for Personalized Medicine, University of Southern California

John Quale Travel Fellows 2014

2013 John Quale Travel Fellows

  • Richard Bambury, MD, BCh, BAO, Memorial Sloan-Kettering Cancer Center
  • Sima Porten, MD, MPH, MD Anderson Cancer Center
  • Srinivas Vourganti, MD, National Cancer Institute
  • Daniel Willis, MD, MD Anderson Cancer Center

travel fellows 2013 1 web

From left to right: Richard Bambury, Srinivas Vourganti, Sima Porten, Daniel Willis



2012 John Quale Travel Fellows

Arjun Balar, MD, an assistant professor at the New York University Cancer Center presented on targeted therapies and markers to predict response and prognosis for bladder cancer.
Jeffrey Bassett, MD, MPH, a fellow in urologic oncology at the Vanderbilt University Medical Center, discussed introducing tobacco screening into urology clinics and using the visit as a teachable moment among bladder cancer survivors.
Eugene Lee, MD, a urologic oncology fellow at the University of Texas MD Anderson Cancer Center, talked about driving laboratory science based on patient needs in bladder cancer – especially adjunct therapies to BCG and chemotherapy
Armine Smith, MD, a urologic oncology fellow at the National Cancer Institute, presented on the need for combination targeted therapy in treating bladder cancer.

(left to right: Diane Quale, BCAN Co-Founder and President; Jeffrey Bassett, Arjun Balar, Armine Smith, Eugene Lee)

2011 Travel Fellows
Meng Chen, PhD, a postdoctoral fellow in the department of epidemiology at the University of Texas MD Anderson Cancer Center, presented on a potential genetic marker of susceptibility to bladder cancer, which also correlates with telomere length.Kenneth Nepple, MD, a fellow in urologic oncology at Washington University in St. Louis, discussed hospital readmission rates (whether patients have to return to the hospital within 90 days) for patients after a radical cystectomy, and what factors might affect readmission rates.Sandip Prasad, MD, a Society of Urologic Oncology Fellow at the University of Chicago, talked about identifying “hot spots” for bladder cancer – geographic areas where bladder cancer is more common than we would expect – and how we can compare those hot spots to what carcinogens people in that area might have been exposed to.Steven Smith, MD, PhD, a pathology resident at the University of Michigan, presented on the potential use of molecular biology to identify which patients are likely to respond to chemotherapy.


(left to right: Sandip Prasad, Kenneth Nepple, Steven Smith, Meng Chen)


2010 John Quale Travel Fellows

Andrew Feifer, MD, a second year fellow in urologic oncology at Memorial Sloan-Kettering Cancer Center, presented on a survey examining chemotherapy use in bladder cancer patients.

Heather Honorѐ Goltz, PhD, LMSW, a NIDDK KURe Scholar in the VA Health Services Research and Development Center of Excellence at the Michael E. DeBakay VA Medical Center, spoke about health literacy in bladder cancer patients.

William Brandt, PhD, a post-doctoral fellow in Pathology at Johns Hopkins University, discussed efforts to target the Notch pathway in bladder cancer stem cells.

Kilian Gust, MD, a post-doctoral fellow at the Vancouver Prostate Centre, presented research on the differential expression of Notch receptors in bladder cancer.


(left to right: Kilian Gust, Amit Patel, Peter O’Donnell, Heather Honorѐ Goltz, Steven Smith, Sandip Prasad, William Brandt, Kenneth Nepple, Meng Chen)


2009 John Quale Travel Fellows

Gayathri Chadalapaka, PhD
David DeGraff, PhD
Peter O’Donnell, MD
Amit Patel, MD

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone